Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Letter of Intent with Darmiyan, Inc. to Explore Use of FDA De Novo Authorized BrainSee(R) AI Platform in Early Alzheimer's Disease Trial Design
Collaboration looks to explore the use of Darmiyan's FDA De Novo authorized BrainSee® imaging platform, authorized for predicting risk of progression to Alzheimer's disease in patients with amnestic mild cognitive impairment, as well as Darmiyan's core technology, the Virtual Microscope, tailored towards use in pharmaceutical clinical trials The goal of the collaboration is to inform the identification, selection and monitoring of the best candidates for cli
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-08-20 7:39 AM EDT | Rhelion Life Sciences Corp.
TempraMed Announces Extension of Maccabi Healthcare Services Agreement
Toronto, Ontario--(Newsfile Corp. - August 20, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology innovator focused on temperature-sensitive medication protection, is pleased to announce that Maccabi Healthcare Services ("Maccabi"), Israel's second-largest health maintenance organization ("HMO"), has exercised its option to extend its agreement with TempraMed for an additional year u
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-08-20 7:00 AM EDT | TempraMed Technologies Ltd.
WELL Health Redeems $70 Million 5.50% Convertible Debentures
Vancouver, British Columbia--(Newsfile Corp. - August 20, 2026) - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) (the "Company" or "WELL"), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, r
Technologies, Logiciels, Soins de santé et hôpitaux, Santé
2026-08-20 6:30 AM EDT | WELL Health Technologies Corp.
Rise Nano Optics Joins the Vision Council, a Leading Optical Trade Association, Expanding Access to Key Optical Relationship
Vancouver, British Columbia--(Newsfile Corp. - August 20, 2026) - Rise Nano Optics Ltd. (CSE: EYE) (OTCQB: RNOLF) (FSE: U9Y) ("Rise" or the "Company"), a health technology company advancing vision care through patented nanotechnology lens solutions, is pleased to announce that it has joined The Vision Council, one of the optical industry's leading trade associations representing hundreds of eyewear manufacturers, lens laboratories, retailers, distributors and technology c
2026-08-20 3:00 AM EDT | Rise Nano Optics Ltd.
Relief AI Inc. Announces Closing of Brokered Private Placement of Subscription Receipts
Toronto, Ontario--(Newsfile Corp. - August 19, 2026) - Relief AI Inc. ("Relief AI" or the "Company") and 1329308 B.C. Ltd. ("132 BC") jointly announce that, further to the joint press releases of July 6, 2026 and July 30, 2026, the Company has closed its "best efforts" brokered private placement through the issuance of 5,723,900 subscription receipts of the Company (each, a "Subscription Receipt") at a price of $1.00 per Subscription Receipt (the "Offering Price
Technologies, Soins de santé et hôpitaux, Santé
2026-08-19 9:09 AM EDT | Relief AI Inc. - DNU
Obesity Medicine Association Announced as Primary Educational Partner of the American Board of Obesity Medicine
Denver, Colorado--(Newsfile Corp. - August 19, 2026) - The Obesity Medicine Association (OMA) is honored to announce that they have been named one of the first Primary Educational Partners (PEPs) of the American Board of Obesity Medicine (ABOM). PEPs are organizations approved by ABOM to offer Core Obesity Medicine CME credit to physicians applying for obesity medicine certification through their Continuing Medical Education (CME) pathway. The partnership program was designed as
Soins de santé et hôpitaux, Santé
2026-08-19 9:00 AM EDT | Obesity Medicine Association
Rhelion Life Sciences Announces Appointment of Samiuddin Khaja as CFO
Toronto, Ontario--(Newsfile Corp. - August 19, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector, is pleased to announce the appointment of Samiuddin Khaja as Chief Financial Officer ("CFO") effective immediately. The appointment comes as Rhelion continues its evolution into a focused, research-led life sciences company following the a
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-08-19 8:14 AM EDT | Rhelion Life Sciences Corp.
BetterLife Pharma Appoints Mahan Chehrenama, DO, as Chief Medical Officer
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, today announced the appointment of Mahan Chehrenama, DO, as Chief Medical Officer. Dr. Chehrenama will lead clinical development for BETR-001, the Company's non-hallucinogenic neuroplastogen advancing toward an Investigational New Drug (IND) appli
2026-08-19 8:00 AM EDT | BetterLife Pharma Inc.
Charlotte's Web Launches Route CBD to Support Californians Who Depend on Full-Spectrum Hemp CBD
Louisville, Colorado--(Newsfile Corp. - August 19, 2026) - Charlotte's Web Holdings, Inc. (TSX: CWEB) (OTCQX: CWBHF), the market leader in hemp extract wellness products, today announced the launch of Route CBD, a multi-city advocacy initiative designed to create access and raise awareness of the growing crisis facing Californians who have lost access to trusted full spectrum hemp CBD products.
2026-08-19 7:07 AM EDT | Charlotte's Web Holdings, Inc.
FloraWorks Advances Patented TruCBN(TM) Platform with Peer-Reviewed Safety Publication and Internal GRAS Conclusion
Portland, Oregon--(Newsfile Corp. - August 18, 2026) - FloraWorks Holdings Inc. ("FloraWorks") today announced significant new scientific and regulatory milestones for TruCBN™, its proprietary high-purity cannabinol (CBN) ingredient, further advancing the company's patented CBN platform. TruCBN™ is produced from hemp-derived CBD using FloraWorks' patented controlled oxidation process, protected under U.S. Patent No. 12,371,412 B2. CBN forms naturally in hemp through o
Technologies, Cannabis, Santé, Producteurs de cannabis
2026-08-18 11:00 AM EDT | FloraWorks
TempraMed Executes Definitive Exclusive Distribution Agreement with TEM in Panama, Advancing Commercial Expansion Across Clinics and Pharmacies
Toronto, Ontario--(Newsfile Corp. - August 18, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-08-18 7:00 AM EDT | TempraMed Technologies Ltd.
Custom Health Achieves 70% Increase in Quarterly Revenue in Q2-2026 and Advances Medication Management Platform with Evergreen Pharmacy and Spencer Health Solutions Acquisitions
For the three months ended June 30, 2026, Custom Health achieved quarterly revenue of US$7.4 million, an increase of 70% from Q2-2025. The results reflect the acquisition of InnovativeRx during the period. The equity pickup for IRX accounts for an acquisition date of June 5, 2026. Proforma Revenue for the combined entity for the 3 months ended June 30, 2026 is US$14.3 million(1). Subsequent to quarter-end, Custom Health entered into a binding letter
Technologies, Pharmaceutique, Santé
2026-08-17 6:07 PM EDT | Custom Health Holdings Inc.
Defence Therapeutics Strengthens Radiopharmaceutical Leadership with Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs
Montreal, Quebec--(Newsfile Corp. - August 17, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to announce the appointment of Ryan Simms, PhD, as Chief Operating Officer ("COO") and Head of Radiopharmaceutical Programs, strengthening the Company's leadership and deve
Biotechnologies, Pharmaceutique, Santé
2026-08-17 3:15 AM EDT | Defence Therapeutics Inc.
Hanf.com Transaction Advances as Neural Therapeutics Receives CSE Conditional Approval
Toronto, Ontario--(Newsfile Corp. - August 14, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") is pleased to announce that it has received conditional approval from the Canadian Securities Exchange (the "CSE") for the listing of the Company's shares following completion of its previously announced fundamental change transaction involving CWE European Holdings Inc. ("CWE"), which operates the Hanf.com business in Germany (
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-08-14 5:01 PM EDT | Neural Therapeutics Inc.
Rhelion Life Sciences Signs Agreement with University Health Network for Randomized Clinical Trial of Psilocybin in Parkinson's Disease Depression
Toronto, Ontario--(Newsfile Corp. - August 14, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psy
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-08-14 8:14 AM EDT | Rhelion Life Sciences Corp.
Cosmo Announces SIX Ticker Symbol Change to "CMHC"
Dublin, Ireland--(Newsfile Corp. - August 14, 2026) - Cosmo N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced that it will change its ticker symbol on the SIX Swiss Stock Exchange from “COPN” to “CMHC”. This change is expected to take effect at the opening of trading on Monday, August 17, 2026. The new ticker symbol,
Soins de santé et hôpitaux, Santé
2026-08-14 1:22 AM EDT | Cosmo Pharmaceuticals N.V.
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 Ended June 30, 2026 and Provides Conference Call Information
Northvale, New Jersey--(Newsfile Corp. - August 13, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the first quarter of fiscal year 2027 ended June 30, 2026 ("First Quarter"). Consolidated revenues for the three-month period ending June 30, 2026, were $32.4 million, a decrease of $7.9 million or approximately 19.5% as compared to the same period of the pri
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-08-13 4:11 PM EDT | Elite Pharmaceuticals, Inc.
Akanda's First Towers & Fiber Increases Recurring Revenue with Completion of 200 KM Fiber Network
Toronto, Ontario--(Newsfile Corp. - August 13, 2026) - Akanda Corp. (NASDAQ: AKAN) ("Akanda") and its 100% owned subsidiary First Towers & Fiber Corp. ("FTF" or the "Company"), an emerging telecommunications infrastructure developer in Mexico, today announced an update on recent operational milestones and expansion progress, underscoring its continued growth in telecommunications infrastructure. Core Business and Tower Operations FTF maintains a portfolio of 28 cellular
Cannabis, Santé, Cultivateurs de cannabis, Producteurs de cannabis
2026-08-13 4:05 PM EDT | Akanda Corp
Adia Med Delivers Record Q2 Results: $485K Revenue, First Net Profit, and Nearly Matches Full-Year 2025 Revenue in First Half
Winter Park, Florida--(Newsfile Corp. - August 13, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and advanced clinical services, today announced financial results for the second quarter ended June 30, 2026, as reported in its Form 10-Q filed with the Securities and Exchange Commission.
Soins de santé et hôpitaux, Santé
2026-08-13 12:07 PM EDT | Adia Med Inc.
Charlotte's Web Reports Second Quarter 2026 Financial Results
Louisville, Colorado--(Newsfile Corp. - August 13, 2026) - Charlotte's Web Holdings, Inc. (TSX: CWEB) (OTCQX: CWBHF) ("Charlotte's Web" or the "Company"), a botanical wellness innovation company and the market leader in cannabidiol (CBD) hemp extract wellness products, today announced results for the quarter ended June 30, 2026. All amounts are expressed in U.S. dollars unless otherwise indicated. "The second quarter fundamentally changed Charlotte's Web's financial position.
2026-08-13 7:07 AM EDT | Charlotte's Web Holdings, Inc.